Bluebird Bio Net Profit Margin 2012-2022 | BLUE

Bluebird Bio net profit margin from 2012 to 2022. Net profit margin can be defined as net Income as a portion of total sales revenue.
Bluebird Bio Net Profit Margin Historical Data
Date TTM Revenue TTM Net Income Net Margin
2022-09-30 $0.01B $-0.45B -7566.67%
2022-06-30 $0.01B $-0.59B -8485.71%
2022-03-31 $0.01B $-0.74B -14720.00%
2021-12-31 $0.00B $-0.82B -20500.00%
2021-06-30 $0.02B $-0.84B -4215.00%
2021-03-31 $0.22B $-0.62B -284.02%
2020-06-30 $0.23B $-0.65B -283.91%
2020-03-31 $0.04B $-0.83B -1881.82%
2019-09-30 $0.05B $-0.72B -1349.06%
2019-06-30 $0.06B $-0.65B -1167.86%
2019-03-31 $0.05B $-0.60B -1184.31%
2018-12-31 $0.06B $-0.56B -1009.09%
2018-09-30 $0.04B $-0.52B -1307.50%
2018-06-30 $0.04B $-0.46B -1269.44%
2018-03-31 $0.05B $-0.38B -848.89%
2017-12-31 $0.04B $-0.34B -933.33%
2017-09-30 $0.03B $-0.29B -852.94%
2017-06-30 $0.03B $-0.29B -1028.57%
2017-03-31 $0.01B $-0.28B -2123.08%
2016-12-31 $0.01B $-0.26B -3757.14%
2016-09-30 $0.01B $-0.24B -3983.33%
2016-06-30 $0.01B $-0.21B -4100.00%
2016-03-31 $0.01B $-0.20B -2475.00%
2015-12-31 $0.01B $-0.17B -1284.62%
2015-09-30 $0.02B $-0.14B -777.78%
2015-06-30 $0.02B $-0.11B -495.65%
2015-03-31 $0.02B $-0.06B -266.67%
2014-12-31 $0.02B $-0.05B -208.33%
2014-09-30 $0.02B $-0.04B -158.33%
2014-06-30 $0.02B $-0.03B -112.50%
2014-03-31 $0.02B $-0.03B -125.00%
2013-12-31 $0.02B $-0.03B -136.84%
2013-06-30 $0.01B $-0.01B -171.43%
2013-03-31 $0.00B $-0.01B -1300.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.521B $0.004B
bluebird bio, Inc. is a clinical-stage biotechnology that is focused on developing gene therapies for severe genetic diseases and cancer. The company has developed a deep pipeline using lentiviral-based gene therapies, T-cell immunotherapy expertise, and gene editing capabilities to treat severe genetic diseases as well as cancer.?The pipeline for severe genetic diseases includes betibeglogene autotemcel (beti-cel) for the treatment of transfusion-dependent ?-thalassemia (TDT).
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $154.040B 9.40
GSK (GSK) United Kingdom $72.263B 9.00
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.195B 19.11
Ginkgo Bioworks Holdings (DNA) United States $3.764B 0.00
Myovant Sciences (MYOV) United Kingdom $2.602B 0.00
Arcus Biosciences (RCUS) United States $1.675B 25.14
Biohaven (BHVN) United States $1.282B 0.00
Emergent Biosolutions (EBS) United States $0.672B 5.28
ADC Therapeutics SA (ADCT) Switzerland $0.388B 0.00
Ambrx Biopharma (AMAM) United States $0.075B 0.00
Enzo Biochem (ENZ) United States $0.069B 0.00
Gelesis Holdings (GLS) United States $0.026B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00